Stay updated with breaking news from Valency Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
07.12.2022 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will host a live webcast to review the Company’s most recent clinical results of the ADVANCE II trial in AML maintenance, which ...
05.12.2022 - Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: 64th Annual Society of ...
The shareholders of Mendus AB (publ) (the “Company”), reg. no 556629-1786, are hereby invited to the extraordinary general meeting (“EGM”) on Friday, 18...
TECH TRANSFER ALIGNS WITH CLINICAL DEVELOPMENT STRATEGY FOR DCP-001 Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced an agreement to... | October 18, 2022
RESULTS UNDERPIN DCP-001’S POTENTIAL AS A NOVEL MAINTENANCE AND INTERVENTIONAL THERAPY IN A MAJOR SOLID TUMOR INDICATION Mendus AB (“Mendus” publ;...